160 related articles for article (PubMed ID: 33178990)
41. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review.
Patard JJ; Saint F; Velotti F; Abbou CC; Chopin DK
Urol Res; 1998; 26(3):155-9. PubMed ID: 9694595
[TBL] [Abstract][Full Text] [Related]
42. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
43. Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients.
Winters WD; Lamm DL
Cancer Res; 1981 Jul; 41(7):2672-6. PubMed ID: 7018669
[TBL] [Abstract][Full Text] [Related]
44. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
45. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
46. Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction bacillus Calmette-Guérin therapy.
Niwa N; Kikuchi E; Matsumoto K; Kosaka T; Mizuno R; Oya M
Urol Oncol; 2018 Feb; 36(2):77.e15-77.e21. PubMed ID: 29097085
[TBL] [Abstract][Full Text] [Related]
47. Six essential conditions for bladder-sparing strategies in bacillus Calmette-Guérin unresponsive bladder cancer.
Shariat SF; Enikeev DV; Mostafaei H
Immunotherapy; 2019 Sep; 11(13):1083-1086. PubMed ID: 31385744
[No Abstract] [Full Text] [Related]
48. Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer.
Liu Y; Lu J; Huang Y; Ma L
J Oncol; 2019; 2019():6230409. PubMed ID: 30984262
[TBL] [Abstract][Full Text] [Related]
49. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
Herr HW; Morales A
J Urol; 2008 Jan; 179(1):53-6. PubMed ID: 17997439
[TBL] [Abstract][Full Text] [Related]
50. Bladder cancer and Th1 chemokines.
Paparo SR; Fallahi P
Clin Ter; 2017; 168(1):e59-e63. PubMed ID: 28488840
[TBL] [Abstract][Full Text] [Related]
51. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
52. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
53. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy.
Luo Y; Chen X; Downs TM; DeWolf WC; O'Donnell MA
J Immunol; 1999 Feb; 162(4):2399-405. PubMed ID: 9973521
[TBL] [Abstract][Full Text] [Related]
54. Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction.
Muthuswamy R; Wang L; Pitteroff J; Gingrich JR; Kalinski P
J Immunother Cancer; 2015; 3():6. PubMed ID: 25806105
[TBL] [Abstract][Full Text] [Related]
55. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
56. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
[TBL] [Abstract][Full Text] [Related]
57. Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
Int J Oncol; 1997 Jul; 11(1):79-86. PubMed ID: 21528183
[TBL] [Abstract][Full Text] [Related]
58. Heat shock proteins 60 and 70 are associated with long-term outcome of T1-stage high-grade urothelial tumors of the bladder treated with intravesical Bacillus Calmette-Guérin immunotherapy.
Mano R; Zilber S; Di Natale RG; Kedar D; Lifshitz DA; Yossepowitch O; Baniel J; Margel D
Urol Oncol; 2018 Dec; 36(12):531.e9-531.e17. PubMed ID: 30337218
[TBL] [Abstract][Full Text] [Related]
59. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of intravesical Bacillus Calmette-Guérin therapy against tumor immune escape in an orthotopic model of bladder cancer.
Huang P; Ma C; Xu P; Guo K; Xu A; Liu C
Exp Ther Med; 2015 Jan; 9(1):162-166. PubMed ID: 25452795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
